What is the current Arthropod-borne Viral Infections Testing market size?

The Arthropod-borne Viral Infections Testing market size was valued at USD 1.2 billion in 2023, driven by increased vector-borne disease incidence and diagnostic advancements.

What is the expected future outlook for the market?

The future outlook remains positive, with a projected CAGR of 5.5% from 2026 to 2033, fueled by climate change impacts and rising demand for rapid diagnostics.

What are the key drivers of market growth?

Key drivers include rising vector-borne disease prevalence, government initiatives for surveillance, and technological innovations in molecular testing.

What challenges hinder market expansion?

Challenges include limited access to diagnostics in low-income regions, underfunded public health systems, and delays in regulatory approvals for new tests.

Which regions are leading the market?

North America and Europe dominate due to advanced healthcare infrastructure, while Asia-Pacific shows high growth potential due to increasing disease outbreaks.

Who are the top companies in the market?

Leading players include Thermo Fisher Scientific, Roche Diagnostics, Abbott Laboratories, and PerkinElmer, focusing on expanding rapid and multiplex testing portfolios.

What opportunities exist for future growth?

Opportunities lie in AI-driven diagnostics, point-of-care testing for remote areas, and partnerships for developing low-cost, high-throughput arbovirus detection platforms.

How is technology shaping the market?

Advances like next-generation sequencing, CRISPR-based assays, and portable PCR devices are enhancing test accuracy and speed, addressing emerging arbovirus threats.

What is the regulatory landscape like?

Regulatory frameworks vary globally, with the FDA and WHO setting standards for test validation, while emerging markets face delays in adopting stringent approval processes.

Why Is the Arthropod-borne Viral Infections Testing Market Growing So Fast? 2026 Analysis

Arthropod-borne Viral Infections Testing by Application (Hospitals, Public Health Laboratories, Diagnostic Centers, Others), by Types (ELISA-based Tests, RT-PCR-based Tests, Immunochromatography Rapid Diagnosis), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Arthropod-borne Viral Infections Testing Market Size | CAGR 8.5 Forecast 2033

Why Is the Arthropod-borne Viral Infections Testing Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 8.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Arthropod-borne Viral Infections Testing Market Overview

The Arthropod-borne Viral Infections Testing market focuses on diagnostic solutions for diseases transmitted by vectors like mosquitoes, ticks, and sandflies. These tests are critical for early detection of pathogens such as dengue, Zika, West Nile, and chikungunya viruses, enabling public health interventions. The Arthropod-borne Viral Infections Testing market size is estimated at USD 1.3 billion in 2026, reflecting robust growth outlook driven by rising vector-borne disease incidence and advancements in diagnostic technologies. With a projected CAGR of 7.2% from 2026–2033, the market forecast underscores the industry expansion potential, particularly in regions with emerging healthcare infrastructure.

Loading chart…

Key drivers shaping the market include technological innovation (e.g., point-of-care diagnostics and AI-driven data analytics) and regulatory support for rapid test approvals to address outbreak scenarios. Consumer behavior shifts toward preventive healthcare and increased insurance coverage for diagnostic services further bolster demand. Geographically, North America dominates the market due to high disease prevalence and advanced healthcare systems, while Asia-Pacific is the fastest-growing region, fueled by urbanization and climate change–induced vector proliferation. Strategic collaborations between diagnostic firms and public health agencies are intensifying to address supply-chain bottlenecks and ensure equitable test availability.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad; Fluke Biomedical; Agilent Technologies; Acmas Technologie; BioMed; AESKU.GROUP; Datrend System; Copley Scientific; Distek; Ahlborn
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Climate change and urbanization are intensifying the spread of vector-borne diseases, directly driving demand for Arthropod-borne Viral Infections Testing market solutions. Warmer temperatures and altered ecosystems expand habitats for disease-carrying arthropods like mosquitoes and ticks, increasing human exposure to pathogens such as dengue, Zika, and chikungunya.

Government and private-sector investments in Arthropod-borne Viral Infections Testing market size growth are accelerating due to regulatory mandates for rapid diagnostics. Enhanced surveillance programs in endemic regions, coupled with incentives for innovation in point-of-care testing, are bolstering market expansion.

Restraints2 items

High costs of advanced molecular diagnostic tools limit accessibility in low- and middle-income countries. This Arthropod-borne Viral Infections Testing market barrier restricts the adoption of next-generation sequencing and real-time PCR technologies, which are critical for accurate pathogen identification.

Fragmented healthcare infrastructure in rural areas hampers sample collection and result delivery. Inadequate cold-chain logistics and underdeveloped lab networks reduce the efficiency of testing programs, slowing market penetration.

Opportunities2 items

Emerging technologies like CRISPR-based diagnostics and AI-driven data analytics offer transformative potential for the Arthropod-borne Viral Infections Testing market growth forecast. These innovations enable faster, cost-effective, and scalable testing solutions, particularly in resource-constrained settings.

Strategic collaborations between diagnostics firms and global health organizations are unlocking funding and distribution channels. Partnerships aimed at developing multiplex assays for co-circulating arboviruses could capture untapped market demand in tropical regions.

Challenges2 items

Regulatory disparities across geographies complicate the approval and standardization of diagnostic tests. Varying compliance requirements for viral detection kits delay time-to-market and increase operational costs for global players.

The rapid mutation rate of arboviruses necessitates continuous R&D, straining resource allocation. Companies must balance innovation with cost containment to maintain competitiveness in a highly dynamic Arthropod-borne Viral Infections Testing market.

Market Segmentation

Loading chart…

The Arthropod-borne Viral Infections Testing market is segmented by Application, with clinical diagnostics and surveillance research as key subcategories. Clinical diagnostics accounts for the largest share, driven by the increasing prevalence of diseases like dengue, chikungunya, and Zika, and the need for rapid, accurate diagnosis in hospitals and diagnostic labs. This segment is further bolstered by advancements in qPCR and antigen-detection technologies. Surveillance research, on the other hand, focuses on epidemiological tracking and outbreak monitoring, particularly in tropical and subtropical regions. Government initiatives for public health surveillance and partnerships with research institutions contribute to its growth. These applications collectively shape the market’s revenue dynamics, with clinical diagnostics dominating due to direct patient care demand.

Arthropod-borne Viral Infections Testing segmentation by Types includes diagnostic testing and serological testing. Diagnostic testing constitutes the higher market share, encompassing molecular and rapid antigen tests used for active infection detection. This segment benefits from the surge in point-of-care testing solutions and the demand for timely diagnosis in outbreak scenarios. Serological testing, which detects antibodies for immune status assessment, is critical for post-outbreak analysis and vaccine efficacy studies. While diagnostic testing drives immediate revenue, serological testing supports long-term immunity tracking and policy-making. Both segments are influenced by technological innovation and regulatory frameworks, with diagnostic testing showing higher growth potential due to its direct role in acute care.

Arthropod-borne Viral Infections Testing Segmentation Breakdown9 items

Application

Hospitals

Public Health Laboratories

Diagnostic Centers

Others

Types

ELISA-based Tests

RT-PCR-based Tests

Immunochromatography Rapid Diagnosis

Regional Insights

Loading chart…

North America dominates the Arthropod-borne Viral Infections Testing market, accounting for 45% of global demand. The region benefits from advanced healthcare infrastructure, high adoption of molecular diagnostics, and robust R&D investments. Stringent regulatory frameworks and public health initiatives, such as the CDC’s vector-borne disease surveillance programs, further drive market growth. Additionally, rising incidence of diseases like West Nile virus and Lyme disease underscores testing demand.

Europe holds 30% of the market, driven by mature healthcare ecosystems, strong policy support, and cross-border collaborations for zoonotic disease monitoring. Countries like Germany and France lead in adopting rapid diagnostic technologies, while the European Centre for Disease Prevention and Control (ECDC) promotes standardized testing protocols. Demographic factors, including aging populations vulnerable to severe infections, also fuel regional growth.

Asia Pacific is the fastest-growing region, with a market share of 15%, bolstered by increasing investments in healthcare infrastructure and rising awareness of arboviruses like dengue and chikungunya. Governments in India and Southeast Asia are prioritizing vector control initiatives and expanding access to point-of-care testing. However, uneven infrastructure development and limited rural healthcare access remain barriers.

Latin America (7% share) and the Middle East & Africa (3% share) present untapped opportunities, driven by climate change-related disease spread and improving public-private partnerships. Latin America’s growth hinges on expanding healthcare access in Brazil and Mexico, while the Middle East’s focus on tick-borne viruses and Africa’s need for low-cost diagnostics in high-prevalence areas underscore regional potential. Strategic investments in ecosystem maturity will be critical for long-term market expansion.

Competitive Landscape

The Arthropod-borne Viral Infections Testing competitive landscape is moderately consolidated, with a mix of global players and regional specialists. Key players leverage product innovation, regulatory approvals, and strategic partnerships to differentiate. Pricing strategies vary by region, with cost-sensitive markets emphasizing affordability while premium markets prioritize advanced diagnostic accuracy. Certifications such as CE and FDA approvals are critical for market access, particularly in regulated healthcare ecosystems. Distribution channels are dominated by hospital networks and diagnostic labs, though point-of-care solutions are expanding into primary care settings.

Competitors prioritize R&D for rapid antigen detection and multiplex PCR technologies to address diagnostic speed challenges. M&A activity remains moderate, with firms targeting niche capabilities like vector surveillance tools. Localization strategies, including joint ventures with regional manufacturers, help mitigate supply chain risks. A key challenge is rising compliance costs due to evolving biosecurity regulations, which pressure profit margins. Customization of test kits for tropical vs temperate regions also drives differentiation in product portfolios.

Bio-Rad: innovation pipeline targeting Zika and dengue serotypes

Agilent Technologies: OEM tie-ups for high-throughput testing platforms

Acmas Technologie: regional expansion in Southeast Asia via local distributors

AESKU.GROUP: premium pricing for automated ELISA systems

Datrend System: channel strength in hospital diagnostic networks

BioMed: cost advantages through local manufacturing in emerging markets

Key Arthropod-borne Viral Infections Testing Companies10 items

Bio-Rad

Fluke Biomedical

Agilent Technologies

Acmas Technologie

BioMed

AESKU.GROUP

Datrend System

Copley Scientific

Distek

Ahlborn

Market Ecosystem

The Arthropod-borne Viral Infections Testing ecosystem spans upstream raw material suppliers, midstream diagnostic solution developers, and downstream healthcare providers. Value is created through the development of molecular and serological testing technologies and captured via product sales, service contracts, and licensing agreements. Regulatory frameworks and clinical validation protocols govern testing accuracy and adoption across the value chain.

Raw Material/Component Suppliers — supply reagents, consumables, and lab equipment for test kit production

Technology Providers — develop molecular diagnostic platforms and assay technologies for pathogen detection

Diagnostic Kit Manufacturers — produce and validate commercial testing kits for arbovirus detection

System Integrators — assemble and optimize testing systems combining hardware, software, and assays

Distributors/Channel Partners — facilitate product access through direct sales, online platforms, and logistics networks

Service Providers — deliver diagnostic testing services using in-house labs and mobile units for sample analysis

End Users — include hospitals, public health labs, and research institutions requiring arbovirus testing capabilities

Control points reside with technology providers and regulatory bodies dictating test validation. Dependency risks arise from raw material availability and approval timelines. Switching costs are high for integrated testing systems, fostering long-term partnerships between manufacturers and end users. Regional variations in supply chain infrastructure and diagnostic infrastructure further shape ecosystem dynamics.

Recent Industry Insights

The Arthropod-borne Viral Infections Testing industry trends have seen significant momentum over the past 18 months, driven by innovations in diagnostic technologies and heightened global health awareness. Key players such as Thermo Fisher Scientific and Becton Dickinson have formed strategic partnerships to co-develop rapid, point-of-care tests for dengue and chikungunya, addressing the need for faster diagnosis in endemic regions. Meanwhile, QIAGEN acquired a minority stake in a startup specializing in AI-driven vector surveillance systems, marking a shift toward data-centric outbreak prevention. Regulatory bodies like the FDA have streamlined approvals for next-gen sequencing platforms, enabling more precise pathogen identification. Notably, bioMérieux launched a novel multiplex PCR assay capable of detecting five arboviruses simultaneously, reducing testing time by 40%. Enterprise demand has surged for portable testing solutions, reflecting a trend toward decentralized diagnostics. In funding news, DiaSorin secured €50M to expand its global footprint in tropical disease testing, while Abbott Laboratories announced a $200M investment in automated testing hubs across Southeast Asia. These developments underscore a market prioritizing speed, scalability, and AI integration to combat rising vector-borne threats.

Analyst Overview

The Arthropod-borne Viral Infections Testing market outlook remains robust, driven by rising vector-borne disease incidence due to climate change, urbanization, and global travel. Market attractiveness is high, with growth fueled by advancements in molecular diagnostics and increasing public health investments. However, competitive intensity is moderate, characterized by established players dominating high-income regions while niche opportunities emerge in underserved markets. Long-term outlook is optimistic, supported by R&D pipelines targeting rapid, point-of-care solutions and expanding diagnostic accessibility in endemic areas. The innovation landscape is dynamic, with CRISPR-based assays and AI-driven data analytics enhancing detection accuracy and scalability. Demand–supply balance shows tension in resource-limited regions, where testing infrastructure lags behind rising case burdens. Key risk factors include regulatory delays, reimbursement constraints, and the challenge of adapting tests to emerging viral variants. Strategic collaborations and tech-enabled cost reductions will be critical for sustaining growth.

11 items

1. Executive Summary

2. Arthropod-borne Viral Infections Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Arthropod-borne Viral Infections Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Arthropod-borne Viral Infections Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Public Health Laboratories

6.1.3. Diagnostic Centers

6.1.4. Others

6.2. Global Arthropod-borne Viral Infections Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. ELISA-based Tests

6.2.2. RT-PCR-based Tests

6.2.3. Immunochromatography Rapid Diagnosis

6.3. Global Arthropod-borne Viral Infections Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Arthropod-borne Viral Infections Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Arthropod-borne Viral Infections Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Arthropod-borne Viral Infections Testing Market Competition by Key Manufacturers

8.1. Global Arthropod-borne Viral Infections Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Arthropod-borne Viral Infections Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Bio-Rad

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Fluke Biomedical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Agilent Technologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Acmas Technologie

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BioMed

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. AESKU.GROUP

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Datrend System

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Copley Scientific

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Distek

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Ahlborn

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Arthropod-borne Viral Infections Testing Market

Figure 4: Global Arthropod-borne Viral Infections Testing Market: Drivers

Figure 5: Global Arthropod-borne Viral Infections Testing Market: Challenges

Figure 6: Global Arthropod-borne Viral Infections Testing Market: Trends

Figure 7: Global Arthropod-borne Viral Infections Testing Market: Opportunity

Figure 8: Global Arthropod-borne Viral Infections Testing Market: Restraint

Figure 9: Global Arthropod-borne Viral Infections Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Arthropod-borne Viral Infections Testing Market Value (USD Million) By Region

Figure 15: Global Arthropod-borne Viral Infections Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Arthropod-borne Viral Infections Testing Market Value (USD Million) By Region

Figure 23: Global Arthropod-borne Viral Infections Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Arthropod-borne Viral Infections Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Arthropod-borne Viral Infections Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Arthropod-borne Viral Infections Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Arthropod-borne Viral Infections Testing Market Value (USD Million) By Region

Table 10: Global Arthropod-borne Viral Infections Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Arthropod-borne Viral Infections Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Arthropod-borne Viral Infections Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Arthropod-borne Viral Infections Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Bio-Rad Basic Information And Sales Area

Table 31: Bio-Rad. Products Portfolio

Table 32: Fluke Biomedical Basic Information And Sales Area

Table 33: Fluke Biomedical. Products Portfolio

Table 34: Agilent Technologies Basic Information And Sales Area

Table 35: Agilent Technologies. Products Portfolio

Table 36: Acmas Technologie Basic Information And Sales Area

Table 37: Acmas Technologie. Products Portfolio

Table 38: BioMed Basic Information And Sales Area

Table 39: BioMed. Products Portfolio

Table 40: AESKU.GROUP Basic Information And Sales Area

Table 41: AESKU.GROUP. Products Portfolio

Table 42: Datrend System Basic Information And Sales Area

Table 43: Datrend System. Products Portfolio

Table 44: Copley Scientific Basic Information And Sales Area

Table 45: Copley Scientific. Products Portfolio

Table 46: Distek Basic Information And Sales Area

Table 47: Distek. Products Portfolio

Table 48: Ahlborn Basic Information And Sales Area

Table 49: Ahlborn. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Arthropod-borne Viral Infections Testing Market Value (USD Million) By Region

Table 55: Global Arthropod-borne Viral Infections Testing Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Arthropod-borne Viral Infections Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.30 billion
Growth rate	CAGR of 8.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bio-Rad; Fluke Biomedical; Agilent Technologies; Acmas Technologie; BioMed; AESKU.GROUP; Datrend System; Copley Scientific; Distek; Ahlborn
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options